Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Million

Series B funds will enable clinical development of ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary ...
Medical News Today

What to know about HHT

Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder that affects the blood vessels. A person with HHT may have blood vessels that have not developed properly and may have no ...

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.
GEN

Rare Bleeding Disorder, HHT, Treated Successfully with Cancer Drug in Clinical Trial

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...